GSK (GSK) said Thursday the UK's Medicines and Healthcare products Regulatory Agency has authorized the use of Blenrep combinations to treat relapsed or refractory multiple myeloma.
Blenrep is now approved for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, GSK said.
The regulator also approved the drug in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy, including lenalidomide, it added.
This authorization marks the first in the world for Blenrep in this treatment setting, the company said.
Price: 35.76, Change: +0.39, Percent Change: +1.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.